Page 3 of 5
Journal of the American Chemical Society
Experimental procedures, compound characterization data, and NMR
spectra for new compounds. This material is available free of charge via
yield
(%)a
ee
entry
1
product
drb
(%)c
1
2
3
4
5
6
7
8
F
9a
9b
9c
71
60
66
96
95
≥20:1
OH
AUTHOR INFORMATION
Corresponding Author
Ph
F
2
3
≥20:1
≥20:1
≥20:1
OH
4-FC6H4
F
98d
9
Notes
OH
The authors declare no competing financial interests.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
4-ClC6H4
F
ACKNOWLEDGMENT
4
5
6
7
9d
9e
9f
75
69
49
74
97
98
85
96
OH
OH
OH
4-BrC6H4
4-CF3C6H4
4-MeOC6H4
This work was supported by the Natural Science and Engineering Re-
search Council of Canada (NSERC), the Canada Foundation for In-
novation, the Canada Research Chair Program, the Centre in Green
Chemistry and Catalysis (CGCC) and Université de Montréal.
L.P.B.B. is grateful to NSERC (PGS D) and Université de Montréal for
postgraduate fellowships. We wish to thank Francine Bélanger for the
X-ray analysis. We thank Genentech for partial support.
F
≥20:1
≥20:1
≥20:1
F
F
9g
OH
REFERENCES
2-MeC6H4
F
8
9h
62
99
≥20:1
OH
Mes
F
1
(a) Müller, K.; Faeh, C.; Diederich, F. Science 2007, 317, 1881. (b) Meanwell,
9
9i
9j
62
70
72
94
96
95
≥20:1
≥20:1
≥20:1
OH
N. A. J. Med. Chem. 2011, 54, 2529.
n-Pr
2
Diederich, F. In Fluorine in Pharmaceutical and Medicinal Chemistry, Gouver-
F
neur, V., Müller, K., Eds.; Imperial College Press: London, UK, 2012, pp v-x.
10
11
3
Vuligonda, V.; Lin, Y.; Chandraratna, R. A. S. Biorg. Med. Chem. Lett. 1996, 6,
TIPSO
OH
213.
4
F
(a) Martin, S. F.; Austin, R. E.; Oalmann, C. J.; Baker, W. R.; Condon, S. L.;
9k
DeLara, E.; Rosenberg, S. H.; Spina, K. P.; Stein, H. H. J. Med. Chem. 1992, 35,
1710. (b) Martin, S. F.; Oalmann, C. J.; Liras, S. Tetrahedron 1993, 49, 3521.
(c) Reichelt, A.; Martin, S. F. Acc. Chem. Res. 2006, 39, 433. (d) Wipf, P.; Xiao,
J. Org. Lett. 2004, 7, 103. (e) Meanwell, N. A. J. Med. Chem. 2011, 54, 2529.
OH
Cy
F
12
13
9l
73
46
82
98
≥20:1
5
Ph
OH
David, E.; Milanole, G.; Ivashkin, P.; Couve-Bonnaire, S.; Jubault, P.;
2
Me
Pannecoucke, X. Chem. Eur. J. 2012, 18, 14904.
6
F
For selected exmamples of monofluorocyclopropanes syntheses, see: (a)
Brahms, D. L. S.; Dailey, W. P. Chem. Rev. 1996, 96, 1585. (b) Morikawa, T.;
Sasaki, H.; Mori, K.; Shiro M.; Taguchi, T. Chem. Pharm. Bull. 1992, 40, 3189.
(c) Meyer, O. G. J.; Fröhlich, R.; Haufe, G. Synthesis 2000, 10, 1479. (d) Naka-
zato, A.; Kumagai, T.; Sakagami, K.; Yoshikawa, R.; Suzuki, Y.; Chaki, S.; Ito,
H.; Taguchi, T.; Nakanishi, S.; Okuyama, S. J. Med. Chem. 2000, 43, 4893. (e)
Saito, A.; Ito, H.; Taguchi, T. Tetrahedron 2001, 57, 7487. (f) Zhang, F. ; Song,
Z. J.; Tschaen, D.; Volante, R. P. Org. Lett. 2004, 6, 3775. (g) Tan, L. S.; Yasuda,
N.; Yoshikawa, N.; Hartner, F. W.; Eng, K. K.; Leonard, W. R.; Tsay, F. R.;
Volante, R. P.; Tillyer, R. D. J. Org. Chem. 2005, 70, 8027. (h) Ivashkin, P.;
Couve-Bonnaire, S.; Jubault, P.; Pannecoucke, X. Org. Lett. 2012, 14, 5130. (i)
Lemonnier, G.; Lion, C.; Quirion, J. C.; Pin, J. P.; Goudet, C.; Jubault, P. Bioorg.
Med. Chem. 2012, 20, 4716.
9m
4:1
OH
Ph
a Isolated yield of the diastereomerically pure material. b Determined
by H NMR from the crude mixture. Determined by SFC on a chiral
The absolute configuration of its O-3,5-
dinitrobenzoyl derivative was determined by X-ray crystallography.
1
c
d
stationary phase.
In summary, we have reported the first highly enantioselective
monofluorocyclopropanation reaction of allylic alcohols. The reaction
features a broad scope and gives access to biologically relevant mono-
fluorocyclopropane units from readily available precursors. Quenching
experiments have confirmed the halogen scrambling at the zinc carbe-
noid, which precedes the cyclopropanation event. This contribution
has overcome the ongoing limitation in Simmons-Smith monofluoro-
cyclopropanations involving the use of FCHI2 as carbenoid precursor.
Further applications of this strategy are ongoing and will be reported in
due course.
7 Shen, X.; Zhang, W.; Zhang, L.; Luo, T.; Wan, X.; Gu, Y.; Hu, J. Angew. Chem.,
Int. Ed. 2012, 51, 6966.
8
For other cyclopropanation methodologies relying on the use of the dioxabo-
rolane ligand, see: (a) Charette, A. B.; Juteau, H. J. Am. Chem. Soc. 1994, 116,
2651. (b) Charette, A. B.; Lemay, J. Angew. Chem., Int. Ed. 1997, 36, 1090. (c)
Charette, A. B.; Juteau, H.; Lebel, H.; Molinaro, C. J. Am. Chem. Soc. 1998, 120,
11943. (d) Goudreau, S. R.; Charette, A. B. J. Am. Chem. Soc. 2009, 131, 15633.
(e) Zimmer, L. E.; Charette, A. B. J. Am. Chem. Soc. 2009, 131, 15624.
9
(a) Beaulieu, L.-P. B.; Zimmer, L. E.; Charette, A. B. Chem. Eur. J. 2009, 15,
ASSOCIATED CONTENT
11829. (b) Beaulieu, L.-P. B.; Zimmer, L. E.; Gagnon, A.; Charette, A. B. Chem.
Eur. J. 2012, 18, 14784.
Supporting Information
10 Charette, A. B.; Beauchemin, A. Org. React. (NY) 2001, 58, 1.
ACS Paragon Plus Environment